Bral

Pain syndrome of mild or moderate severity in smooth muscle spasms (renal and biliary colic, intestinal spasm, dysmenorrhea, etc.), neuralgia, arthralgia, myalgia, pain after diagnostic and surgical interventions, fever in colds and infectious and inflammatory diseases.

Inside, preferably after eating.

Adults: and children over 15 years of age 1-2 tablets. 2-3 times a day, the maximum daily dose of 6 tablets.

For children: only as prescribed by a doctor: 6-8 years 1/2 table., 9-12 years-3/4 table., 13-15 years-1 table. 2-3 times a day. The duration of the reception is not more than 5 days.

Hypersensitivity, severe liver and kidney function disorders, congenital glucose−6-phosphate dehydrogenase deficiency, tachyarrhythmia, collaptoid state, hematopoietic disorder, angle-closure glaucoma, intestinal obstruction, megacolon, prostatic hypertrophy with a tendency to accumulate residual urine, pregnancy (first trimester and last 6 weeks), breast-feeding, childhood (up to 6 years).

From the nervous system and sensory organs: dizziness, in isolated cases — headache.

From the cardiovascular system and blood (hematopoiesis, hemostasis): decreased blood pressure, tachycardia, thrombocytopenia, leukopenia, agranulocytosis.

Allergic reactions: skin rash, itching, very rarely-anaphylactic shock, with a tendency to bronchospasm, it is possible to provoke an attack.

Other: dry mouth, burning sensation in the epigastric region (in isolated cases), cyanosis.

• NSAIDs-Pyrazolones in combinations

Tricyclic antidepressants, oral contraceptives, allopurinol, disrupt liver metabolism and increase toxicity. The effect is enhanced by sedatives and tranquilizers, weakened by barbiturates, phenylbutazone, etc. inducers of microsomal liver enzymes. Other non-narcotic analgesics potentiate side effects, and cyclosporine reduces plasma levels.

In a dry place, protected from light, at a temperature not exceeding 25 °C.

Keep out of reach of children.

Do not use after the expiration date indicated on the package.

1 tablet contains metamizole sodium 500 mg, pitofenone hydrochloride 5 mg and fenpiverinium bromide 0.1 mg, in a contour cell package of 10 pcs., in a box of 10 packages.

Contraindicated in the first trimester and in the last 6 weeks of pregnancy. Breastfeeding should be discontinued for the duration of treatment.

The metabolites of metamizol can color the urine red.

N02BB52 Metamizole sodium in combination with other drugs other than psycholeptics

• K80. 5 Bile duct stones without cholangitis or cholecystitis
• M25. 5 Joint pain
• M79. 1 Myalgia
• M79. 2 Neuralgia and neuritis, unspecified
• N23 Renal colic, unspecified
• N94. 4 Primary dysmenorrhea
• N94. 5 Secondary dysmenorrhea
• N94. 6 Dysmenorrhea, unspecified
• R10. 4 Other and unspecified abdominal pain
• R50. 0 Fever with chills
• R52. 0 Acute pain
• R52. 9 Pain, unspecified
• Z100* CLASS XXII Surgical Practice
• Z40 Preventive surgery